- Home
- PETS vs ACRS Comparison
PETS vs ACRS Comparison
Compare PETS & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PETS | ACRS |
|---|---|---|
| Founded | 1996 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.6M | 311.0M |
| IPO Year | 2003 | 2015 |
Fundamental Metrics
Financial Performance| Metric | PETS | ACRS |
|---|---|---|
| Price | $2.29 | $4.20 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $3.20 | ★ $9.75 |
| AVG Volume (30 Days) | 81.6K | ★ 2.5M |
| Earning Date | 02-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 18.92 | ★ 69.01 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $273,800,000.00 | $1,683,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.98 | $4.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.57 | $1.05 |
| 52 Week High | $4.32 | $4.89 |
Technical Indicators
Market Signals| Indicator | PETS | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 36.60 | 66.39 |
| Support Level | N/A | $2.67 |
| Resistance Level | $2.93 | $4.89 |
| Average True Range (ATR) | 0.11 | 0.26 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 25.00 | 98.04 |
Price Performance
Historical ComparisonAbout PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.